51. RAD52 Facilitates Mitotic DNA Synthesis Following Replication Stress
- Author
-
Rahul Bhowmick, Ian D. Hickson, and Sheroy Minocherhomji
- Subjects
DNA Replication ,0301 basic medicine ,Mitosis ,Eukaryotic DNA replication ,Biology ,03 medical and health sciences ,Replication factor C ,Control of chromosome duplication ,Stress, Physiological ,Cell Line, Tumor ,Humans ,Molecular Biology ,DNA Polymerase III ,BRCA2 Protein ,Genetics ,Endodeoxyribonucleases ,Osteoblasts ,DNA synthesis ,Chromosome Fragile Sites ,DNA replication ,Recombinational DNA Repair ,DNA ,Cell Biology ,Endonucleases ,Rad52 DNA Repair and Recombination Protein ,Cell biology ,DNA-Binding Proteins ,030104 developmental biology ,Licensing factor ,Origin recognition complex ,Rad51 Recombinase ,Homologous recombination ,DNA Damage ,HeLa Cells - Abstract
Homologous recombination (HR) is necessary to counteract DNA replication stress. Common fragile site (CFS) loci are particularly sensitive to replication stress and undergo pathological rearrangements in tumors. At these loci, replication stress frequently activates DNA repair synthesis in mitosis. This mitotic DNA synthesis, termed MiDAS, requires the MUS81-EME1 endonuclease and a non-catalytic subunit of the Pol-delta complex, POLD3. Here, we examine the contribution of HR factors in promoting MiDAS in human cells. We report that RAD51 and BRCA2 are dispensable for MiDAS but are required to counteract replication stress at CFS loci during S-phase. In contrast, MiDAS is RAD52 dependent, and RAD52 is required for the timely recruitment of MUS81 and POLD3 to CFSs in early mitosis. Our results provide further mechanistic insight into MiDAS and define a specific function for human RAD52. Furthermore, selective inhibition of MiDAS may comprise a potential therapeutic strategy to sensitize cancer cells undergoing replicative stress.
- Published
- 2016